Boehringer goes earlier than Bayer
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
ESMO 2025 preview – Enhertu's early breast hat-trick
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
Chia Tai broadens its biparatopic breast cancer approach
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
ASCO 2025 – Enhertu mounts its first-line charge
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
AACR 2025 – Boehringer still has broad zongertinib hopes
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
